Oncology trial operations

Multiple myeloma clinical trial operations

Myeloma studies can bring prior treatment records, response assessments, and transplant or laboratory schedules into one review. Give each dependency a clear owner before opening a cohort or setting a data milestone.

Where study execution gets difficult

Multiple myeloma is a cancer of plasma cells. In relapsed or refractory cohorts, prior regimens, drug-class exposure, and response history can be spread across institutions. For a response or measurable residual disease (MRD) endpoint, a completed visit can still leave an incomplete assessment if a required specimen, central result, or companion lab value is missing.

What the study team can do

Start with the protocol and lab manual. Reconcile the assessment date, specimen or accession identifier, lab status, and EDC record before closing the action. Have the Senior CRA follow site evidence and have the study manager coordinate the lab and data teams on unresolved items. The sponsor sets the endpoint and escalation rules.

When this handoff needs a sponsor decision, use an executive briefing to clarify who owns it and what evidence will guide the decision.

Request an executive briefing →

What each role can own

Oncology CRA

Track the protocol-required specimen, collection dates, and reports and reconcile the source with data entry.

CTM or Clinical Study Manager

Agree who follows lab status and who escalates incomplete results before an endpoint or maintenance review.

Cross-site monitoring review

Group recurring prior-line discrepancies, missed transplant handoffs, and late marrow or lab results by site and cause.

A Lead CRA can coordinate recurring findings. For scoped SIGNAL Managed Monitoring, a named review lead brings patterns and open actions to the sponsor’s decision owners.

What to put in the staffing brief

  1. Agree which prior lines, drug classes, and dated response or progression evidence each site must document.
  2. Map marrow, serum, urine, and central lab deliverables to the protocol’s required assessment windows where applicable.
  3. Distinguish a visit marked complete from an assessment packet ready for review. Name the decision owner for unresolved exceptions.

Related experience and references

Preparing oncology sites for database lock →